Advertisements


GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology

GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology.....»»

Category: topSource: seekingalphaFeb 11th, 2019

GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy......»»

Category: topSource: reutersFeb 5th, 2019

GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion

U.K.-based GlaxoSmithKline Plc  and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday......»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline and Merck KGaA to strike immunotherapy deal worth up to $4.23 billion

U.K.-based GlaxoSmithKline plc a.....»»

Category: topSource: marketwatchFeb 5th, 2019

GlaxoSmithKline, Merck KGaA to collaborate on cancer treatments

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck KGaA to receive upfront payment of about $342.8 mln as part of GlaxoSmithKline collaboration

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck KGaA could receive up to about $4.2 bln in milestone payments as part of GlaxoSmithKline deal

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchFeb 5th, 2019

Merck, Bristol-Myers profits rise on cancer drug sales

Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments......»»

Category: topSource: reutersOct 25th, 2018

BioLineRx expands immuno-oncology collaboration with Merck

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 30th, 2018

Merck upgraded to Overweight on immuno-oncology leadership at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (NASDAQ:CGIX), a leader in enabling precision medicine for immuno-oncology and genomic .....»»

Category: earningsSource: benzingaApr 16th, 2019

Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals

Germany's Merck KGaA sealed a $6.5 billion takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris......»»

Category: topSource: reutersApr 12th, 2019

Merck KGaA to hold a conference call

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 12th, 2019

Merck KGaA to acquire Versum Materials for $53 per share

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 12th, 2019

Merck KGaA to buy Versum in all-cash deal valued at 5.8 billion euros

Merck KGaA said Friday it has signed a definitive agreement to acquire .....»»

Category: topSource: marketwatchApr 12th, 2019

Merck KGaA agrees $6.5 billion takeover of Versum

Germany's Merck KGaA said it signed a takeover agreement with target Versum Materials for a price of $53 per share after Versum walked away from a prior merger agreement with rival Entegris......»»

Category: topSource: reutersApr 12th, 2019

Merck KGaA in definitive agreement to acquire Versum in deal with enterprise value of 5.8 bln euros

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Merck KGaA expects deal to immediately boost earnings per share

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Merck KGaA expects deal to close in second half

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Versum Materials Says Revised Merck KGaA Buyout Proposal "Superior" To Entegris Offer

Versum Materials, Inc. (NYSE: VSM) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  read more.....»»

Category: blogSource: benzingaApr 8th, 2019

Versum Materials Says Revised Merck Buyout Proposal "Superior" To Entegris Offer

Versum Materials, Inc. (NYSE: VSM) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  read more.....»»

Category: blogSource: benzingaApr 8th, 2019